Diabetes Dialogue: Implications of SELECT Trial and Brenzavvy on Cost Plus Drugs

from Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives · host Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives

In this episode, hosts take time to break down the implications of two, potentially paradigm-shifting news in the announcement of the addition of bexagliflozin to the Cost Plus Drugs platform and topline data from the landmark SELECT trial.Video version: https://www.hcplive.com/view/diabetes-dialogue-implications-of-select-trial-and-brenzavvy-on-cost-plus-drugs

Episode metadata supplied by the publisher feed · Published Aug 23, 2023

Embed this episode

Attribution link and audio player

NOW PLAYING

Diabetes Dialogue: Implications of SELECT Trial and Brenzavvy on Cost Plus Drugs

0:00 33:19

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives?

This episode is 33 minutes long.

When was this Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives episode published?

This episode was published on August 23, 2023.

Can I download this Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!